Skip to main content
. 2016 Sep 16;7(45):73817–73829. doi: 10.18632/oncotarget.12074

Figure 3. SHP2 positively regulate ERK1/2 and AKT signaling pathways.

Figure 3

A. SHP2 overexpression promotes dephosphorylation of pPaxillin(Y118) and pSrc(Y527), as well as ERK1/2, AKT and S6K activation. Consistently, SHP2 knockdown attenuates dephosphorylation of pPaxillin(Y118) and pSrc(Y527), as well as ERK1/2, AKT and S6K activation under B. non-stimulation or C. HGF stimulation.